These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 32732848

  • 21. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
    Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R.
    Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
    [Abstract] [Full Text] [Related]

  • 22. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T, Tomosugi T, Futamura K, Okada M, Nishihira M, Goto N, Ichimori T, Narumi S, Kobayashi T, Uchida K, Watarai Y.
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [Abstract] [Full Text] [Related]

  • 23. Timing of mTORI usage and outcomes in kidney transplant recipients.
    Lim LM, Kung LF, Kuo MC, Huang AM, Kuo HT.
    Int J Med Sci; 2021 Feb; 18(5):1179-1184. PubMed ID: 33526978
    [Abstract] [Full Text] [Related]

  • 24. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ.
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [Abstract] [Full Text] [Related]

  • 25. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S, Akl EA, Azzi JR.
    Clin J Am Soc Nephrol; 2017 Aug 07; 12(8):1321-1336. PubMed ID: 28576905
    [Abstract] [Full Text] [Related]

  • 26. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E, Ratto E, Bellino D, Marsano L, Cassottana P, Cannella G.
    J Nephrol; 2012 Aug 07; 25(5):709-18. PubMed ID: 22038336
    [Abstract] [Full Text] [Related]

  • 27. Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients.
    Pascual J, Berger SP, Chadban SJ, Citterio F, Kamar N, Hesselink DA, Legendre C, Eisenberger U, Oppenheimer F, Russ GR, Sommerer C, Rigotti P, Srinivas TR, Watarai Y, Henry ML, Vincenti F, Tedesco-Silva H.
    Transplant Rev (Orlando); 2019 Oct 07; 33(4):191-199. PubMed ID: 31377099
    [Abstract] [Full Text] [Related]

  • 28. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B, Zhang S, MacConmara M, Gao A, Sandikci B, Ayvaci MU, Mete M, Tsapepas D, Rajora N, Mohan P, Lakhia R, Lu CY, Vazquez M.
    Clin J Am Soc Nephrol; 2015 Jun 05; 10(6):1041-9. PubMed ID: 25979971
    [Abstract] [Full Text] [Related]

  • 29. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
    Saliba F, Rostaing L, Gugenheim J, Durand F, Radenne S, Leroy V, Neau-Cransac M, Calmus Y, Salamé E, Pageaux GP, Duvoux C, Taguieva N, Sinnasse-Raymond G, Sebagh M, Samuel D, Marquet P.
    Transplantation; 2016 Aug 05; 100(8):1705-13. PubMed ID: 27454919
    [Abstract] [Full Text] [Related]

  • 30. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
    Toniato de Rezende Freschi J, Cristelli MP, Viana LA, Ficher KN, Nakamura MR, Proença H, Dreige YC, de Marco R, de Lima MG, Foresto RD, Aguiar WF, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2024 Jan 01; 108(1):261-275. PubMed ID: 37525373
    [Abstract] [Full Text] [Related]

  • 31. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators.
    Lancet; 2011 Mar 05; 377(9768):837-47. PubMed ID: 21334736
    [Abstract] [Full Text] [Related]

  • 32. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.
    Chadban SJ, Eris JM, Kanellis J, Pilmore H, Lee PC, Lim SK, Woodcock C, Kurstjens N, Russ G, SOCRATES Study Group.
    Transpl Int; 2014 Mar 05; 27(3):302-11. PubMed ID: 24279685
    [Abstract] [Full Text] [Related]

  • 33. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J, Couchonnal E, Lacaille F, Rivet C, Debray D, Boillot O, Lachaux A, Ackermann O, Gonzales E, Wildhaber BE, Jacquemin E, McLin V.
    Clin Res Hepatol Gastroenterol; 2019 Aug 05; 43(4):403-409. PubMed ID: 30528864
    [Abstract] [Full Text] [Related]

  • 34. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
    Phanish MK, Hull RP, Andrews PA, Popoola J, Kingdon EJ, MacPhee IAM, South West Thames Renal Transplantation Network.
    BMC Nephrol; 2020 Mar 11; 21(1):92. PubMed ID: 32160893
    [Abstract] [Full Text] [Related]

  • 35. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.
    Transpl Infect Dis; 2016 Feb 11; 18(1):79-88. PubMed ID: 26707694
    [Abstract] [Full Text] [Related]

  • 36. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
    Albano L, Alamartine E, Toupance O, Moulin B, Merville P, Rerolle JP, Tetaz R, Moal MC, Kamar N, Legendre C, Quéré S, Di Giambattista F, Terpereau A, Dantal J.
    Ann Transplant; 2012 Feb 11; 17(1):58-67. PubMed ID: 22466910
    [Abstract] [Full Text] [Related]

  • 37. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X, Jiang Y, Lai X, Xiang S, Shou Z, Chen J.
    BMC Nephrol; 2015 Jul 01; 16():91. PubMed ID: 26126806
    [Abstract] [Full Text] [Related]

  • 38. Treatment with everolimus is associated with a procoagulant state.
    Baas MC, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ.
    Thromb Res; 2013 Aug 01; 132(2):307-11. PubMed ID: 23906938
    [Abstract] [Full Text] [Related]

  • 39. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T, Yoshimura N, Ushigome H, Watarai Y, Nishimura K, Akioka K, Nakamura N, Kawakita M, Yuzawa K, Nakatani T.
    Int J Urol; 2018 Feb 01; 25(2):141-145. PubMed ID: 29068092
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients.
    Brunkhorst LC, Fichtner A, Höcker B, Burmeister G, Ahlenstiel-Grunow T, Krupka K, Bald M, Zapf A, Tönshoff B, Pape L.
    PLoS One; 2015 Feb 01; 10(9):e0135439. PubMed ID: 26407177
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.